Journal
ANNALS OF THE RHEUMATIC DISEASES
Volume 71, Issue 6, Pages 857-861Publisher
BMJ PUBLISHING GROUP
DOI: 10.1136/annrheumdis-2011-200355
Keywords
-
Categories
Funding
- Bristol-Myers Squibb
- Abbott Laboratories
- AstraZeneca Pharma
- Biotest
- Bristol-Myers Squibb Company
- Centocor, Inc
- F Hoffmann-La Roche Inc
- Genentech Inc
- Merck
- Nycomed
- Pfizer Pharmaceuticals
- UCB
- Amgen Inc
- AstraZeneca Pharmaceuticals LP
- Genzyme
- Novartis Pharmaceuticals
- Centocor Ortho Biotech Inc
- Genentech
- Genentech and Biogen IDEC Inc
- Merck Pharmaceuticals
- Ortho Biotech Products L P
- Pfizer Inc
- Roche
- UCB, Inc
- Human Genome Sciences, Inc
- Ortho Biotech Products LP
- Roche Diagnostics
- GlaxoSmithKline
Ask authors/readers for more resources
Objective To assess safety, immunogenicity and efficacy in rheumatoid arthritis (RA) patients switched from long-term intravenous to subcutaneous (SC) abatacept. Methods In this phase IIIb, open-label, single-arm trial, patients who completed >= 4 years of intravenous abatacept (in long-term extensions of two phase III studies) were enrolled to receive SC abatacept (125 mg/week). The primary objective was safety during the first 3 months after switching from intravenous therapy. Results 123 patients entered the study (mean Disease Activity Score 28 (based on C reactive protein) and HAQ-DI of 3.4 and 0.94, respectively). At month 3, 120 (97.6%) patients were continuing to receive SC abatacept; no patients discontinued due to lack of efficacy. Adverse events (AEs) were reported in 49 (39.8%) patients through month 3. One patient (0.8%) discontinued due to an AE and one patient (0.8%) experienced a serious AE. Two (1.6%) patients had SC injection site reactions (erythema, pain), both with mild intensity. Clinical efficacy was maintained throughout. Limited impact on immunogenicity was observed when switching routes of administration. Conclusion These data demonstrate that patients can switch from long-term monthly intravenous abatacept to a weekly fixed dose of 125 mg SC abatacept with no increased safety concerns. This study further supports SC abatacept as an alternative treatment option for patients with RA.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available